Chinese biotech firm Gracell nets $100m from Wellington, OrbiMed, others

Chinese biotech firm Gracell nets $100m from Wellington, OrbiMed, others

Photo by Dmitry Bayer on Unsplash

Chinese clinical-stage biopharmaceutical firm Gracell Biotechnologies Inc. has completed a $100 million Series C round co-led by the US investment company Wellington Management, New York-based OrbiMed Healthcare Fund Management, and VC firm 5Y Capital (formerly Morningside Venture Capital), the investee company said on Wednesday.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter